, Tracking Stock Market Picks
Enter Symbol:
C.r. Bard, Inc. (BCR) [hlAlert]

down 55.99 %

C.r. Bard, Inc. (BCR) rated Underweight with price target $87 by Barclays Capital

Posted on: Friday,  Sep 23, 2011  1:25 PM ET by Barclays Capital

Barclays Capital rated Underweight C.r. Bard, Inc. (NYSE: BCR) on 09/23/2011, when the stock price was $86.46. Since
then, C.r. Bard, Inc. has gained 127.26% as of 01/20/2016's recent price of $196.49.
If you would have followed this Barclays Capital's recommendation on BCR, you would have lost 55.99% of your investment in 1580 days.

C.R. Bard, Inc. is one of the worldwide leaders in developing, manufacturing, and supplying healthcare products that focus on Vascular, Urology, and Oncology Disease States. In addition, Bard offers a complete line of advanced Surgical Specialty products and services that address needs in hernia repair, performance irrigation, hemostasis, and other areas.

Barclays Capital has assembled a world-class, award-winning team of analysts covering, credit, commodities, economics, emerging markets, equities, fixed income, foreign exchange and market strategy. We provide in-depth analysis of companies and macro coverage across asset classes, markets and the world’s economies. We have a highly quantitative approach and our research is underpinned by sophisticated analytics. Combined, these provide clients with the tools and insights necessary for successful risk management and financing. Our research teams are based in many of the world’s major financial centres providing our clients with a globally integrated perspective across products and geographies.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/23/2011 1:25 PM Sell
86.46 87.00
as of 12/30/2011
1 Week down  -0.44 %
1 Month up  1.93 %
3 Months up  2.33 %
1 YTD up  1.11 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy